J Neuhaus1, E Schiffer, J Siwy, F Mannello, L-C Horn, J-U Stolzenburg. 1. Department für Operative Medizin, Klinik und Poliklinik für Urologie, Universitätsklinikum Leipzig AöR, Liebigstraße 20, 04103, Leipzig, Deutschland, jochen.neuhaus@medizin.uni-leipzig.de.
Abstract
BACKGROUND: Due to comprehensive PSA screening, the incidence for prostate cancer (PCa) is rising. Therefore, there is an urgent need for improved PCa diagnostics and prognostic tools to differentiate between insignificant and aggressive, fast growing tumors. METHODS: With the proteome-based method presented here, we were able to distinguish PCa from BPH, chronic prostatitis and healthy controls with 83 % sensitivity and 67 % specificity. Furthermore, the methods discerned advanced PCa from local, organ-confined PCa in a group of patients with gleason score 7 (80 % sensitivity, 82 % specificity). RESULTS: Our proteomic approach is based on the analysis of low molecular weight polypeptides, identified as the endpoint of the naturally occuring liquefaction cascade in seminal plasma. For the first time using seminal plasma as a source, we analysed a complex network of interacting proteases and specific inhibitors, reflecting tumor biology specificity. Our diagnostic and prognostic tool is robust and easy to handle, and therefore it is well suitable for the laboratory and medical practice.
BACKGROUND: Due to comprehensive PSA screening, the incidence for prostate cancer (PCa) is rising. Therefore, there is an urgent need for improved PCa diagnostics and prognostic tools to differentiate between insignificant and aggressive, fast growing tumors. METHODS: With the proteome-based method presented here, we were able to distinguish PCa from BPH, chronic prostatitis and healthy controls with 83 % sensitivity and 67 % specificity. Furthermore, the methods discerned advanced PCa from local, organ-confined PCa in a group of patients with gleason score 7 (80 % sensitivity, 82 % specificity). RESULTS: Our proteomic approach is based on the analysis of low molecular weight polypeptides, identified as the endpoint of the naturally occuring liquefaction cascade in seminal plasma. For the first time using seminal plasma as a source, we analysed a complex network of interacting proteases and specific inhibitors, reflecting tumor biology specificity. Our diagnostic and prognostic tool is robust and easy to handle, and therefore it is well suitable for the laboratory and medical practice.
Authors: Xiaoju Wang; Jianjun Yu; Arun Sreekumar; Sooryanarayana Varambally; Ronglai Shen; Donald Giacherio; Rohit Mehra; James E Montie; Kenneth J Pienta; Martin G Sanda; Philip W Kantoff; Mark A Rubin; John T Wei; Debashis Ghosh; Arul M Chinnaiyan Journal: N Engl J Med Date: 2005-09-22 Impact factor: 91.245
Authors: Runsheng Li; Yan Guo; Bang Ming Han; Xiaowei Yan; Angelita G Utleg; Wei Li; Lan Chun Tu; Jian Wang; Leroy Hood; Shujie Xia; Biaoyang Lin Journal: Proteomics Clin Appl Date: 2008-04-01 Impact factor: 3.494
Authors: David K Ornstein; Walter Rayford; Vincent A Fusaro; Thomas P Conrads; Sally J Ross; Ben A Hitt; Wesley W Wiggins; Timothy D Veenstra; Lance A Liotta; Emanuel F Petricoin Journal: J Urol Date: 2004-10 Impact factor: 7.450
Authors: Dan Theodorescu; Stefan Wittke; Mark M Ross; Michael Walden; Mark Conaway; Ingo Just; Harald Mischak; Henry F Frierson Journal: Lancet Oncol Date: 2006-03 Impact factor: 41.316
Authors: Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman Journal: N Engl J Med Date: 2004-05-27 Impact factor: 91.245